Value of accelerated multimodality therapy in stage IIIA and IIIB non–small cell lung cancer
- 1 July 2003
- journal article
- clinical trial
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 126 (1), 17-25
- https://doi.org/10.1016/s0022-5223(03)00206-x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and ImplicationsJournal of Clinical Oncology, 2000
- Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancerThe Annals of Thoracic Surgery, 1998
- Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancerThe Annals of Thoracic Surgery, 1995
- Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.Journal of Clinical Oncology, 1995
- Results of cancer and leukemia group B protocol 8935The Journal of Thoracic and Cardiovascular Surgery, 1995
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- The Decomposition of Time-Varying Hazard into Phases, Each Incorporating a Separate Stream of Concomitant InformationJournal of the American Statistical Association, 1986
- Biologic basis for altered fractionation schemesCancer, 1985
- Accelerated fractionation vs hyperfractionation: Rationales for several treatments per dayInternational Journal of Radiation Oncology*Biology*Physics, 1983